Our APIs are engineered with precision and purity, ensuring consistent therapeutic performance and global regulatory compliance.
Enteric Coated Pellets • Sustained Release Pellets • Micro Pellets • DC Granules • APIs
Sulfur-bearing benzimidazole intermediate supporting Lansoprazole, Rabeprazole, and Dexlansoprazole synthesis. Delivered with tight impurity and residual solvent controls for reliable PPI manufacturing (CAS 583-39-1). End use: Lansoprazole, Rabeprazole, Dexlansoprazole.
Key benzimidazole intermediate for methoxy-substituted proton pump inhibitors. Managed particle control and sulphur profile aid consistent downstream coupling (CAS 37052-78-1). End use: Lansoprazole, Rabeprazole, Dexlansoprazole.
Activated pyridine salt used in assembling the Omeprazole side chain. Controlled chloromethyl content and low colour ensure clean coupling reactions (CAS 86604-75-3). End use: Omeprazole.
Coupled benzimidazole intermediate feeding final Omeprazole formation. Produced under nitrogen with sulphide controls to minimise oxidative by-products (CAS 73590-85-9). End use: Omeprazole.
Difluoromethoxy benzimidazole scaffold enabling Pantoprazole sulphide formation. Managed fluoride content supports regulatory-compliant impurity profiles (CAS 97963-62-7). End use: Pantoprazole.
Chloro pyridine intermediate (Pantoprazole chloro) optimised for high assay and controlled chloride levels, expediting nucleophilic substitution with benzimidazole partners (CAS 72830-09-2). End use: Pantoprazole.
Pantoprazole sulphide intermediate manufactured under controlled oxidation states to facilitate clean sulfoxidation steps (CAS 102625-64-9). End use: Pantoprazole.
Ethoxy-substituted benzimidazole intermediate supporting Afobazol and Obenoxazine syntheses. Produced with low residual solvents to simplify downstream crystallisation (CAS 55489-15-1). End use: Afobazol, Obenoxazine.
Activated pyridine salt that anchors Rabeprazole side-chain construction. Chloride and moisture controls deliver consistent coupling performance (CAS 153259-31-5). End use: Rabeprazole.
As India's leading pellets manufacturer, we offer pharmaceutical pellets R&D pilot scale development, pellet coating services India, third party manufacturing tablets India, and contract manufacturing pharma India. Our CDMO India team provides DMF access, stability data, pharmaceutical technology transfer services, and custom formulations for omeprazole, lansoprazole, domperidone SR, and tamsulosin SR pellets.